Toniv,

It is not fair to compare CANTOS to BETonMACE. CANTOS was a Phase 3 trial that met its primary endpoints with statistical significance showing a reduction in cardiovascular events. It proved that there is indeed cardiovascular outcomes benefit from anti-inflammatory therapy. Apabetalone is still in its first Phase 3 trial, BETonMACE. When the ongoing BETonMACE trial is completed, and if and when apabetalone proves to reduce cardiovascular events, then this molecule will also "rouse quite a bit of excitement amongst clinicians and researchers." This will especially be true if the relative risk reduction for 3-point MACE meets or exceeds 30%, and will be even more exciting if the effects include a significant reduction in cardiovascular death.

BearDownAZ